Its very unlikley that the current vaccine won't be effective on the variants whether in Kent or other variants especially when it comes to severe illness and hospitalisation.
The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.
Pfizer said it expects there could be a long-lasting need for COVID-19 vaccines, to combat new virus variants that emerge and to "boost" peoples' waning immune responses.
"BioNTech/Pfizer will deliver 75 million of additional doses in the second quarter of the year - and up to 600 millions in total in 2021," von der Leyen wrote on Twitter.
He said that Covid-19 test collection teams have also been deputed to conduct test at door to door from coming Wednesday in ten severely coronavirus hit districts of province.
A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95% effective in preventing symptomatic illness in pivotal trials when given in two doses.
J&J's main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85% effective in stopping severe disease.
Once delivered, the vaccines must be administered by already overstretched medical workers. A Kyodo News survey showed about 80% of prefectural governments were concerned about having enough staff to give injections.
The WHO signed an advance purchase agreement with the American pharmaceutical, where it will receive at least 40 million doses of the drug.
It also anticipates another 50 million doses from UK-based pharmaceutical Oxford-Astrazeneca. As per the existing agreement with the company, the shipment will be made in first quarter of the year.